Patients must have unresectable stage III or stage IV disease
Patients must have stage II, III, or IV disease
Patients with confirmed stage IV disease
Has stage III or stage IV disease that is not surgically resectable.
Diagnosed with Stage IV resectable disease
CLL (Part ): Rai Stage III or IV disease, or stage -II disease that meets National Cancer Institute Working Group (NCIWG) criteria for active disease requiring therapy that may include either of the following disease-related symptoms:
Stage I, II, III, or IV disease; NOTE: stage I disease are eligible only if the disease is not amenable to external beam radiation therapy
Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in first partial response (PR) or after progression if stage I/II <  year; stage III/IV patients are eligible after progression in CR/PR
Patients must have stage II-IV disease
Inoperable per local Investigator (Masaoka stage III or IV)
Stage  or Stage IV BC
Lymphoblastic lymphoma, Burkitts lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR/PR or after progression if stage I/II <  year
Has stage IV or recurrent disease that has been treated
Patients with stage III-IV HER negative breast cancer treated with primary or salvage therapy and now have:\r\n* No evidence of disease (NED), or \r\n* Stable bone only disease
Patients may have advanced unresectable stage IV disease, resectable stave IV disease or recently resected stage IV disease (< weeks prior) with no apparent disease.
Disease must be stage III or IV
Lymphoblastic lymphoma, Burkitts lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR/PR or after progression if stage I/II <  year
Stage IV disease
Lymphoblastic lymphoma, Burkitts lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR/PR or after progression if stage I/II <  year
Stage IV disease
Stage IV disease
HER- negative breast cancer that at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is available
Clinical stage III or IV
All Stage IV patients are eligible, irrespective of residual disease, after primary or interval debulking. Stage III patients are required to have visible residual disease after primary surgery. Patients with inoperable Stage III and IV disease are eligible
Breast cancer, which at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is available
Stage II, III, or IV disease
Patients with initial diagnoses of stage IV disease
Stage IV disease diagnosed within  weeks of randomization
Stage IV disease (measurable disease NOT required)
Stage II, III, or IV disease
FIGO stage IA, IB, II, III or IV disease
Stage III/IV disease (stage II is also eligible if disease is not encompassible within a single radiation field)
Stage IB, II-A, II-B, III and IV
Extent of disease: stage I - IV; patients with nodular histology mantle cell lymphoma must have Ann Arbor stage III or IV disease to be eligible\r\n* Patients with mantle zone type histology will not be eligible\r\n* Patients with other mantle cell histologies are eligible regardless of stage
Intra-abdominal desmoid disease, stage III or IV
Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=]  centimeters [cm])
Stage IV disease
Patients with Rai stage III-IV - OR - Patients with Rai stage -II
FIGO stage II-IV;
Stage II, III or IV cardiac failure
Unresectable Stage III or IV disease
Diagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage III/IV
Patient must have measurable stage IV disease (includes Ma, Mb stages or recurrent disease) (according to the th edition of the TNM classification system); however, patients with TNX disease (stage III B) with nodule(s) in ipsilateral lung lobe are not eligible, because such patients were not included in historical controls
Stage IV disease at the start of first-line chemotherapy
Patients with stage IV disease with no more than five metastases in no more than two visceral organ sites will be eligible; if a multidisciplinary tumor board determines trial entry for an individual patient with stage IV exceeding this number of metastases is appropriate, that patient can be enrolled
Stage II, III or IV disease
Stage II disease with bulky disease (? cm lesion), Stage III, or Stage IV disease
Stage IV disease or inoperable locally advanced disease.
The patient has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease
The participant has Stage IV disease at the time of study entry.
Treatment with investigational parenteral anti-influenza drugs (IV peramivir, IV zanamivir or IV oseltamivir) in the  weeks prior to Baseline.
Stage IV disease at the time of study entry
Patients must have suspected International Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease
Localized endometrial cancer (stage I and II); no evidence of stage III or IV disease
Mallampati IV
Patients with stage IV disease will be excluded from the study
Diagnosed with stage IV disease
Patients diagnosed with GOLD Stage IV Emphysema.
The patient has diagnosis of stage IV disease or is found to have stage IV disease prior to randomization
Patients with a diagnosis of advanced stage disease (stage III or IV)